New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group

Critical Reviews in Oncology/Hematology

Volumn 109, Issue , 2017, Pages 35-41

  Cortinovis, Diego ^a   Gregorc, Vanesa ^b   Migliorino, Maria Rita ^c   Abate, Maria Ida ^a   Manzo, Anna ^d   Malapelle, Umberto ^e   Morabito, Alessandro ^d  

^a H S Gerardo   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atezolizumab; Docetaxel; Nintedanib; Nivolumab; Non squamous NSCLC; Pembrolizumab; Ramucirumab; Second line therapy; Therapeutic strategy

Indexed keywords

ANGIOGENESIS INHIBITOR; ATEZOLIZUMAB; DOCETAXEL; ERLOTINIB; IFOSFAMIDE; NAVELBINE; NINTEDANIB; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; STEROID; TUMOR MARKER; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; TAXOID;

AUTOIMMUNE DISEASE; BLEEDING TENDENCY; CANCER IMMUNOTHERAPY; COMORBIDITY; DISEASE COURSE; DISEASE MARKER; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GENE MUTATION; HUMAN; ITALY; MEDICAL DECISION MAKING; MONOTHERAPY; NON SMALL CELL LUNG CANCER; ONCOLOGIST; OVERALL SURVIVAL; PATIENT SELECTION; REVIEW; SMOKING; VIRUS HEPATITIS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDOLES; ITALY; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 85006341339     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.11.015     Document Type: Review

References (19)

1. Barlesi, F, Park, F, Ciardiello, F et al., Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. ESMO 2016, Abstract LBA44_PR.
2. Barni, S., Maiello, E., Di Maio, M., et al. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. Lung Cancer 90:2 (2015), 234–242.
3. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639.
4. de Marinis, F., Ardizzoni, A., Fontanini, G., et al. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. Clin. Lung Cancer 15:5 (2014), 338–345.
5. Di Maio, M., Perrone, F., Chiodini, P., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 25:11 (2007), 1377–1382.
6. European Medicines Agency, Opdivo (nivolumab): EU summary of product characteristics. 2016. http://ec.europa.eu/ (Accessed 8 August 2016).
7. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:10030 (2016), 1837–1846.
8. Fossella, F.V., DeVore, R., Kerr, R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18:12 (2000), 2354–2362.
9. Garon, E.B., Ciuleanu, T.E., Arrieta, O., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:9944 (2014), 665–673.
10. Gridelli, C., Ardizzoni, A., Barni, S., et al. Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational SUN (Survey on the lUng cancer maNagement) study. Lung Cancer 74:3 (2011), 462–468.
11. Hanna, N., Shepherd, F.A., Fossella, F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22:9 (2004), 1589–1597.
12. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
13. Novello, S., Kaiser, R., Mellemgaard, A., et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur. J. Cancer 51:3 (2015), 317–326.
14. Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K.M., Peters, S., on behalf of the ESMO Guidelines Working Group, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25:Suppl. 3 (2014), 27–39.
15. Reck, M., Heigener, D., Reinmuth, N., Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Rev. Clin. Pharmacol. 7:5 (2014), 579–590.
16. Reck, M., Kaiser, R., Mellemgaard, A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15:2 (2014), 143–155.
17. Reck, M., Rodríguez-Abreu, D., Robinson, A., et al. Pembrolizumab or chemotherapy in PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med., 2016, 10.1056/NEJMoa1606774.
18. Shepherd, F.A., Dancey, J., ramlau, R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:10 (2000), 2095–2103.
19. Shepherd, F.A., Pereira, J.R., Ciuleanu, T., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353:2 (2005), 123–132.